CAR-T and other adoptive cell therapies for B cell malignancies
B cell malignancies pose challenges due to therapeutic resistance and repeated relapse. Advances in adoptive cellular therapies including chimeric antigen receptor (CAR)-T cells have the potential to transform the treatment landscape in hematological and solid tumor cancers. Improvements in construc...
Saved in:
Main Authors: | Peihua Lu, Holly A. Hill, Lucy J. Navsaria, Michael L. Wang |
---|---|
Format: | article |
Language: | EN |
Published: |
Elsevier
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/13baf7e057a4433f9f07fc68916d37eb |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation
by: Virginia Picanço-Castro, et al.
Published: (2021) -
Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
by: Christopher Sloas, et al.
Published: (2021) -
Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers
by: Mehran Bahraini, et al.
Published: (2021) -
Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
by: Cristina Aparicio, et al.
Published: (2021) -
How Can We Engineer CAR T Cells to Overcome Resistance?
by: Glover M, et al.
Published: (2021)